MeiraGTx stock surges on Hologen AI deal

Investing.com -- Shares of MeiraGTx Holdings plc (Nasdaq: NASDAQ:MGTX) climbed 13% following the announcement of a strategic collaboration with Hologen AI, aimed at accelerating the Phase 3 development of AAV-GAD for Parkinson’s Disease and enhancing the company’s manufacturing processes.

The London and New York-based clinical stage genetic medicines company disclosed the partnership on March 13, 2025, revealing substantial financial commitments from Hologen AI. MeiraGTx is set to receive $200 million in upfront cash and will form a joint venture with Hologen called Hologen Neuro AI Ltd. This venture will be supported by an additional $230 million from Hologen, designated for the complete financing of the AAV-GAD program through to its commercialization, as well as the advancement of other early-stage clinical programs.

In this groundbreaking collaboration, MeiraGTx retains a 30% ownership stake in the joint venture and will take the lead on all clinical development and manufacturing activities. Additionally, Hologen will acquire a minority stake in MeiraGTx’s manufacturing subsidiary, contributing to its annual funding and leveraging AI technologies to optimize MeiraGTx’s proprietary manufacturing processes.

MeiraGTx’s AAV-GAD program has shown promise, with positive data from its randomized, sham-controlled clinical bridging study announced in October 2024. The study demonstrated significant improvement in the Unified Parkinson’s Disease Rating Scale and quality of life measures, bolstering the potential of AAV-GAD as a treatment for Parkinson’s disease.

The CEO of MeiraGTx, Dr. Alexandria Forbes, expressed enthusiasm about the partnership’s potential to enhance the robustness and success probability of the AAV-GAD Phase 3 clinical study. She highlighted the financial significance of the transaction, which provides MeiraGTx with a substantial cash infusion and funds a portion of its manufacturing operations, while retaining significant equity value in the fully funded late-stage Neuro-AI company.

The transactions are subject to customary closing conditions and are expected to be finalized in the second quarter of 2025. This strategic move has clearly resonated with investors, as evidenced by the uptick in MeiraGTx’s stock price, reflecting confidence in the company’s enhanced prospects for developing treatments for neurological disorders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.